Immunotherapy advisory council for urothelial cancer

1. von der Maase H., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77. DOI: 10.1200/JCO.2000.18.17.3068.

2. von der Maase H., Sengelov L., Roberts J.T. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602–8. DOI: 10.1200/JCO.2005.07.757.

3. De Santi M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/ vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30(2):191–9. DOI: 10.1200/JCO.2011.37.3571.

4. Raggi D., Miceli R., Sonpavde G. et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 2016;27(2):49–61. DOI: 10.1093/annonc/mdv509.

5. Balar A.V. IMvigor210, ASCO 2018. Abstract 4523; poster 349.

6. Merseburger A.S. EAU 2019, Plenary Session – Plenary Session 5 BN: Breaking news session.

7. Powles T. et al. EAS 2017, IMvigor211.

8. Balar A.V. ASCO-GU 2019. Abstract 394.

9. Wang Y., Zhou S., Yang F. et al. Treatmentrelated adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 2019. DOI: 10.1001/jamaoncol.2019.0393.

10. NCCN Guidelines for Bladder Cancer 03; 2019.

11. Boyd Z. CRI-CIMT-EATI-AACR 2015. Abstract B001.

12. Petrylak D.P. ASCO 2015.